Institutional Repository UDD

A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus

Show simple item record

dc.contributor.author Vial, Pablo
dc.contributor.author Valdivieso, Francisca
dc.contributor.author Calvo, Mario
dc.contributor.author Rioseco, María
dc.contributor.author Riquelme, Raúl
dc.contributor.author Araneda, Andrés
dc.contributor.author Tomicic, Vinko
dc.contributor.author Graf, Jerónimo
dc.contributor.author Paredes, Laura
dc.contributor.author Fiorenzano, Matías
dc.contributor.author Bidart, Teresa
dc.contributor.author Cuiza, Analía
dc.contributor.author Marco, Claudia
dc.contributor.author Hjelle, Brian
dc.contributor.author Ye, Chunyan
dc.contributor.author Hanfelt-Goade, Daniel
dc.contributor.author Vial, Cecilia
dc.contributor.author Rivera, Juan
dc.contributor.author Delgado, Iris
dc.contributor.author Mertz, Gregory
dc.contributor.author Hantavirus Study Group in Chile
dc.date.accessioned 2017-05-08T12:20:48Z
dc.date.available 2017-05-08T12:20:48Z
dc.date.issued 2015
dc.identifier.citation Antivir Ther. 2015;20(4):377-86 es_CL
dc.identifier.uri https://doi.org/10.3851/IMP2875 es_CL
dc.identifier.uri http://hdl.handle.net/11447/1212
dc.description.abstract BACKGROUND: In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. We designed an open trial to explore safety and efficacy and evaluate pharmacokinetics of immune plasma as a treatment strategy for this disease. METHODS: We performed plasmapheresis on donors at least 6 months after HCPS and measured NAb titres through a focus-reduction neutralization test. Subjects admitted to 10 study sites with suspected/confirmed HCPS were eligible for treatment with immune plasma by intravenous infusion at an ANDV NAb dose of 5,000 U/kg. HCPS was confirmed through immunoglobulin M serology or reverse transcriptase-PCR. The main outcome was mortality within 30 days. RESULTS: From 2008-2012, we enrolled and treated 32 cases and confirmed HCPS in 29. CFR of hantavirus plasma-treated cases was 4/29 (14%); CFR of non-treated cases in the same period in Chile was 63/199 (32%; P=0.049, OR=0.35, CI=0.12, 0.99); CFR of non-treated cases at the same study sites between 2005-2012 was 18/66 (27%; (P=0.15, OR=0.43, CI=0.14, 1.34) and CFR in a previous methylprednisolone treatment study was 20/60 (33%; P=0.052, OR=0.32, CI=0.10, 1.00). We detected no serious adverse events associated to plasma infusion. Plasma NAb titres reached in recipients were variable and viral load remained stable. CONCLUSIONS: Human ANDV immune plasma infusion appears safe for HCPS. We observed a decrease in CFR in treated cases with borderline significance that will require further studies for confirmation. es_CL
dc.format.extent 10 es_CL
dc.language.iso en_US es_CL
dc.publisher International Medical Press es_CL
dc.subject Antibodies, Neutralizing es_CL
dc.subject Antibodies, Viral es_CL
dc.subject Hantavirus Infections es_CL
dc.subject Heart es_CL
dc.subject Immune Sera es_CL
dc.subject Lung es_CL
dc.subject RNA, Viral es_CL
dc.subject Hantavirus/immunology es_CL
dc.title A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus es_CL
dc.type Artículo es_CL


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account